AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06405425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT05192083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management and Support
Description: A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
Study NCT05836987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFSW Guided DOAC
Description: The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
Study NCT05836987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous DOAC therapy
Description: DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
Study NCT05171725 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinician assessment
Description: standard clinical assessment by an expert clinician in the respective field of brain disorders
Study NCT05208632 — intervention group
Intervention type: OTHER
Intervention: INTERSCALEN BLOCK APPLICATION WITH USG
Description: 40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
Study NCT05783765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heightened Drive to Eat
Description: Participants' eating rate and eating in the absence of hunger will be assessed during a videotaped experimental meal. The relative reinforcing value of food will be assessed using a computerized behavioral choice task.
Study NCT05839509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH001
Description: GH001 administered via inhalation
Study NCT05497882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Learning Prototype for Dementia Care
Description: Usability testing System Usability Scale
Study NCT04667429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: HEC83518 40mg will be taken orally fasted or with food
Study NCT04667429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC83518
Description: HEC83518 will be taken orally before sleep for 15 days
Study NCT04667429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo will be administered before sleep for 15 days.
Study NCT05223712 — intervention group
Intervention type: OTHER
Intervention: Diagnostic Test: Chronic Kidney Diseases
Description: The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
Study NCT06689098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetocardiography scan
Description: The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.
Study NCT06006273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given by vein (IV)
Study NCT06006273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by vein (IV)
Study NCT06006273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given by PO
Study NCT06705998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAR502 single dose
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg).
Study NCT06705998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Study NCT06705998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAR502 multiple doses
Description: The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.
Study NCT04740749 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compress Compliant Pre-Stress System
Description: Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
Study NCT06737445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation alone
Description: RTL was performed as a single session using the radiofrequency ablation device (NeuroTherm JK4A; NeuroTherm Ltd, Croydon, London, England).
Study NCT06737445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone Injection
Description: An injection of 1 ml of betamethasone 40 mg/ml and 2 ml of bupivacaine 5 mg/ml was performed.
Study NCT06737445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy
Description: Patients underwent 3 ESWT sessions applied to the plantar heel area, once a week with the same ESWT dose (15 Hz, 2000 pulse, 4.0 bar energy density) using a BTL-5000 SWT device (BTL Industries, USA).
Study NCT05103735 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: awake neurosurgery under propofol-remifentanil sedation
Study NCT03492268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CART
Description: After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
Study NCT05004454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis BS50 spore preparation
Description: Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
Study NCT05004454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
Study NCT05395273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Ready cryocompression
Description: Cryotherapy on the coldest tolerable level and intermittend compression on the knee
Study NCT06742983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isobutyl cyanoacrylate
Description: Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution
Study NCT06742983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2%)
Description: Chlorhexidine Digluconate 0.2%
Study NCT06742983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9% NaCl)
Description: Sodium chloride 0.9%
Study NCT05534607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ola Mau i ka Hula
Description: The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly.
Study NCT05275413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-based mHealth Intervention
Description: The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
Study NCT05275413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mother-only mHealth Intervention
Description: The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
Study NCT05275413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
Study NCT06741631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence.
Study NCT06743048 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue Sparing Laser Implantation
Description: A penile implant will be implanted using the cavernosal sparing technique and assisted by a laser fibre optic
Study NCT06742515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab plus Reduced-dose Chemotherapy
Description: Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.
Study NCT06741943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump (model: AR-B200A)
Description: USE insulin pump (model: AR-B200A) and continuous glucose monitoring (FreeStyle Libre)
Study NCT06741787 — intervention group
Intervention type: DRUG
Intervention: Patients desensitized by sublingual spray
Description: Drug: Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
Study NCT04903509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1820237
Description: BI 1820237
Study NCT06742593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT027 cells suspension
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Study NCT04903509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04903509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda®
Description: Saxenda®
Study NCT04903509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxenda®
Description: Saxenda®
Study NCT04903509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol-ratiopharm®
Description: Paracetamol-ratiopharm®
Study NCT04903509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol-ratiopharm®
Description: Paracetamol-ratiopharm®
Study NCT05186532 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dry Heat Application
Description: 50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
Study NCT05186532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moist Heat Application
Description: included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
Study NCT06481189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-086
Description: The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.
Study NCT06481189 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ilaris®
Description: The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.
Study NCT06388369 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Description: 2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals
Study NCT06388369 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [177Lu]Lu-PSMA-617
Description: 2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals
Study NCT06388369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
Study NCT05837260 — intervention group
Intervention type: OTHER
Intervention: Sample collection only
Description: Sample collection only
Study NCT05753111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA
Description: PEA supplementation
Study NCT05753111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Maltodextrin supplementation
Study NCT05056480 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
Study NCT06070129 — intervention group
Intervention type: PROCEDURE
Intervention: surgical pulmonary embolectomy
Description: open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
Study NCT05418361 — intervention group
Intervention type: DRUG
Intervention: ACE inhibitor ,angiotensin receptor blockers
Description: patients taking ACEI or ARBs with cardiovascular disease
Study NCT05413447 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital consult
Description: Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
Study NCT04777084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI318
Description: IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
Study NCT05590039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyEllevate Procedure
Description: The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline.
Study NCT05955573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: xray
Description: radiological description
Study NCT06478628 — intervention group
Intervention type: BEHAVIORAL
Intervention: Inpatient rehabilitation
Description: Inpatient multimodal rehabilitation in specialist health care
Study NCT06478628 — intervention group
Intervention type: BEHAVIORAL
Intervention: Outpatient day rehabilitation
Description: Multimodal rehabilitation in specialist health care with program lasting whole work days
Study NCT05117489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 150 mg
Description: Miricorilant 150 mg for oral dosing
Study NCT05117489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 100 mg
Description: Miricorilant 100 mg for oral dosing
Study NCT05117489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 50 mg
Description: Miricorilant 50 mg for oral dosing
Study NCT05117489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant 10 mg
Description: Miricorilant 10 mg for oral dosing.
Study NCT06463860 — intervention group
Intervention type: DEVICE
Intervention: DermDx
Description: DermDx is a computer-aided diagnosis (CADx) software product that uses an AI-based algorithm to evaluate non-invasively captured images of skin lesions obtained from any commercially available dermoscopes. DermDx uses state-of-the-art deep neural network models that have been trained on a large database of dermoscopy images. DermDx analyzes the image of a new skin lesion and provides an output.
Study NCT05806593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Back pilot
Description: A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
Study NCT05354544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose derived SVF
Description: A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
Study NCT06483893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided thyroid cartilage plane block (group TCPB)
Description: Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
Study NCT06483893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided traditional superior laryngeal nerve block (group traditional SLNB)
Description: Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
Study NCT06249477 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wrist activity tracker and scale
Description: Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.
Study NCT06249477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist activity tracker and scale
Description: Wrist activity tracker used to evaluate number of steps, heart rate, and frequency of usage of the devices to monitor activity. Scale used to record a patient's weight value.
Study NCT06249477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Coaching group sessions
Description: Nutritional coaching group sessions held via zoom and performed by a certified clinical nutritionist regarding nutrition, and physical activity specific for weight loss.
Study NCT06488105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
Description: moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)
Study NCT06488105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Counseling
Description: Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework